Clinical trials: Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients with moderate to severe Vulvovaginal Candidiasis…
- Trial name
- NCT02679456
- Testing
- SCY-078, Fluconazole
- Where
- 2 sites in Dominican Republic
- Volunteers
- 96 people
- Sponsor
- Scynexis, Inc.
Vaginosis, Bacterial, Candidiasis, Vulvovaginal
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
This is a study to compare the safety and efficacy of the use of a intravaginal ovule containing a combination of Ketoconazole and Clindamycin to the use of an intravaginal cream containing a combination Tetracycline and…
- Trial name
- NCT01293643
- Testing
- 100 mg clindamycin /800 mg ketoconazole vaginal ovule, 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Vulvovaginal Candidiasis
Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis
This single-center, randomized, single-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of oral Lactobacillus crispatus Lc-G22 as adjunctive therapy to clotrimazole for preventing recurrence of…
- Trial name
- NCT07727967
- Testing
- Lactobacillus crispatus Lc-G22
- Where
- China
- Volunteers
- 100 people
- Sponsor
- BioGrowing Co., Ltd
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species…
- Trial name
- NCT02267382
- Testing
- VT-1161
- Where
- 32 sites in United States
- Volunteers
- 254 people
- Sponsor
- Viamet
Vulvovaginal Candidiasis (VVC)
Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis
Open-label, randomized clinical trial with a control group and a 4-week intervention period. The study will evaluate the efficacy of the probiotic supplement Bioithas WOMAN® as an adjunctive treatment in women with clinically…
- Trial name
- NCT07603895
- Testing
- Bioithas WOMAN®
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Bioithas SL
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- NCT03734991
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 376 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms
Women diagnosed with Vulvovaginal Candidiasis by the health care professional will be enrolled in the study. All participants should fulfil inclusion and exclusion criteria. The study product will be used for 5 days, once a day.
- Trial name
- NCT05552378
- Testing
- Multi-Gyn FloraFem
- Where
- Poland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Karo Pharma AB
Vulvovaginal Candidiasis
The Study Of Fluconazole For Vulvovaginal Candidiasis
As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas.
- Trial name
- NCT01806623
- Testing
- Fluconazole
- Where
- 10 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Pfizer
Candidiasis, Vaginosis, Bacterial
Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
The purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference…
- Trial name
- DOBO (NCT02860845)
- Testing
- Boric acid and probiotics, Antibiotic (Clindamycin), Antifungal (Clotrimazole)
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Laboratorios Ordesa
Acute Vulvovaginal Candidiasis
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole In Subjects with Acute vulvovaginal Candidiasis
- Trial name
- NCT04956419
- Testing
- SHR8008 capsule, Fluconazole capsule
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Candidiasis, Vulvovaginal, Mycoses
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
The purpose of this study is to determine if two topical formulations of CD101 are safe and effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC) compared to oral fluconazole.
- Conditions
- Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal
- Trial name
- NCT02733432
- Testing
- CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%)
- Where
- 24 sites in United States
- Volunteers
- 126 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.
Recurrent Vulvovaginal Candidiasis
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months.
- Trial name
- ultraVIOLET (NCT03840616)
- Testing
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule
- Where
- 33 sites in United States
- Volunteers
- 219 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Candidiasis, Vulvovaginal
Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis
This study aims to evaluate the effect of a specific strain of Saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis.
- Trial name
- NCT02859493
- Testing
- Saccharomyces cerevisiae
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Lesaffre International
Vulvo-vaginal Candidiasis
Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis
This study aims to evaluate the effect of a specific strain of Saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis.
- Trial name
- NCT02345096
- Testing
- Saccharomyces cerevisiae
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Lesaffre International
Vulvovaginal Candidiasis
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
The purpose of this study is to evaluate the efficacy and safety of different doses of Venus association in the treatment of vulvovaginal candidiasis.
- Trial name
- NCT05031481
- Testing
- Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4
- Sponsor
- EMS
Vulvovaginal Candidiasis
A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
This was a study that compared the efficacy and safety of a generic butoconazole nitrate vaginal cream, 2% to Gynazole-1 (butoconazole nitrate) Vaginal Cream, 2% in the treatment of vulvovaginal candidiasis caused by Candida…
- Trial name
- NCT01039584
- Testing
- Butoconazole Nitrate Vaginal Cream, Gynazole 1 vaginal cream
- Where
- United States
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- Padagis LLC
Candidiasis, Vulvovaginal
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
The trial medicinal product (Lcr Regenerans®) is obtained from the culture of a strain of Lactobacillus rhamnosus Lcr35®. By virtue of the freeze-drying technique, Lactobacillus rhamnosus Lcr35® is a live bacterium administered…
- Trial name
- GYNOCANS (NCT02251093)
- Testing
- Lcr Regenerans
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Probionov
Vaginal Candidiasis
Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Vulvovaginal candidiasis (VVC) is a common infection among women that is associated with considerable morbidity and health-care cost. 75% of women will suffer of Candida infection for at least one time in their life.
- Trial name
- NCT00915629
- Testing
- Lactibiane candisis 5M
- Where
- France
- Volunteers
- 134 people
- Sponsor
- PiLeJe